Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Hansoh Pharmaceutical Group Company Limited ( (HK:3692) ) has provided an announcement.
Hansoh Pharmaceutical Group Company Limited has announced the grant of restricted share units (RSUs) under its Post-IPO RSU Scheme, involving 8,560,990 shares to 776 grantees, including one executive director and 775 employees. This move is part of the company’s strategy to incentivize its workforce, aligning their performance with the company’s goals, and potentially enhancing its market position by retaining key talent.
More about Hansoh Pharmaceutical Group Company Limited
Hansoh Pharmaceutical Group Company Limited is a pharmaceutical company incorporated in the Cayman Islands, focusing on the development, manufacturing, and sale of innovative drugs. The company operates in the healthcare industry and is listed on the Hong Kong Stock Exchange.
YTD Price Performance: 38.31%
Average Trading Volume: 10,617,561
Technical Sentiment Signal: Sell
Current Market Cap: HK$142.1B
See more insights into 3692 stock on TipRanks’ Stock Analysis page.